BioSpace News Archive

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced the publication of the interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) in the New England Journal of Medicine Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group. REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab.

Context Therapeutics Inc. announced that it has entered into definitive securities purchase agreements for a private placement with accredited investors of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock, which will result in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting placement offering expenses.

Altamira Therapeutics Ltd. today announced that the first patient has been randomized in its trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis.

Visby Medical, a leading medical diagnostic company, announced results from the cross-sectional single visit patient outcomes and implementation study, which evaluated self-collected vaginal swab samples from 55 women using the Visby Medical Sexual Health Click Test for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment.

Philadelphia-based National Disease Research Interchange announces the election of Paul M. Lieberman, Ph.D., to its Board.

BioSig Technologies, Inc. today announced the appointment of Gray Fleming as Chief Commercial Officer.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), today announced that Health Canada has approved oral TPOXX® (tecovirimat) as an extraordinary use new drug.

New Swiss Office Launches International Effort to Expand the Market for Company’s Breakthrough Floré Custom Probiotics.